Further shuffling at Leo Pharma as dermatology drugmaker splits R&D

Danish dermatology drugmaker Leo Pharma said it will split its R&D operations into two separate teams.

The company had about 6,000 employees in early 2022 but, at the time, said it would eliminate 1,000 positions in two years. Then, this January, Leo said it would further reduce headcount by about 300 positions in a rehashing of its sourcing model to emphasize external help in finding orals, topicals and biologics. Leo now says it employs 4,700 people worldwide.